Rilotumumab

Phase 3Monoclonal antibody

Amgen

Rilotumumab is one of 188 biologic programs targeting Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

187

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Malignant Pleural MesotheliomaActive, not recruiting

AdenocarcinomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Fallopian Tube CancerActive, not recruiting

Gastric CancerActive, not recruiting

Lung CancerPreclinical

Active, not recruiting

Malignant Pleural MesotheliomaPhase 2

Active, not recruiting

AdenocarcinomaPhase 3

Active, not recruiting

Metastatic Colorectal CancerPhase 1/Phase 2

Active, not recruiting

Fallopian Tube CancerPhase 2

Active, not recruiting

Gastric CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

714 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 3

20 2

Rilotumumab

Amgen

Phase 3

1 3

Sonesitatug Vedotin

AstraZeneca

Phase 3

1 4

Gemzar

Johnson & Johnson

Preclinical

—5

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

3 6

S1,

CChinese Academy of Medical Sciences

Preclinical

17 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

3 8

Glutamine

Sanofi

Preclinical

1 9

Induction Phase1

Genmab

Preclinical

1 10

Human Albumin

TTonghua Anrate Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lung Cancer2 trials

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Terminated·SSWOG Cancer Research Network·Phase 2/3·NCT02926638·9 enrolled

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Completed·SSWOG Cancer Research Network··NCT02154490·1,864 enrolled

Malignant Pleural Mesothelioma1 trial

AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT01105390

Advanced Solid Tumors1 trial

Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ

Completed· Amgen logo

Amgen·Phase 1·NCT01791374·21 enrolled

Fallopian Tube Cancer1 trial

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Completed·GGynecologic Oncology Group·Phase 2·NCT01039207·31 enrolled

Gastric Cancer1 trial

A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer

Terminated· Amgen logo

Amgen·Phase 3·NCT02137343·34 enrolled

2 more indications

Adenocarcinoma1 trial

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Terminated· Amgen logo

Amgen·Phase 3·NCT01697072·609 enrolled

Metastatic Colorectal Cancer1 trial

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

Completed·NNantBioScience, Inc.·Phase 1/2·NCT00788957·177 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Rilotumumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rilotumumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rilotumumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Amgen

Rilotumumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lung Cancer2 trials

Malignant Pleural Mesothelioma1 trial

Advanced Solid Tumors1 trial

Fallopian Tube Cancer1 trial

Gastric Cancer1 trial

Adenocarcinoma1 trial

Metastatic Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News